What is the main difference between CJC-1295 and sermorelin?

Duration of action. Both are GHRH analogs built on the same GHRH(1-29) fragment and act on the same pituitary receptor, but sermorelin reproduces the native hormone and degrades within minutes (fleeting action), while CJC-1295 — especially in its DAC form — binds albumin and extends its effect over days. They share a mechanism; they differ in how long they last. This answer is educational, not medical advice.

Why is sermorelin said to have had clinical use and CJC-1295 not?

Because sermorelin was FDA-approved as Geref, for GH-deficiency diagnosis (1990) and for pediatric growth hormone deficiency (1997), before being discontinued for commercial reasons around 2008-2009. CJC-1295 never had approval: its human evidence is limited to short-duration pharmacology studies in healthy volunteers. It is a difference in track record, not in current approval: today neither is an approved medicine for general use.

Are they approved today for performance or anti-aging use?

No. Neither is approved by the FDA, EMA, or MHRA for performance or anti-aging use; they are handled as research-use-only (RUO) substances, and sermorelin only retains a compounding pathway by prescription in the US. As GH secretagogues, both are additionally prohibited at all times for competitive athletes under WADA's S2 category. This information is educational.

← Guides

CJC-1295 vs Sermorelin: two GHRH analogs

CJC-1295 and sermorelin always come up together in the conversation about growth hormone secretagogues, and for good reason: both are analogs of growth hormone-releasing hormone (GHRH) and both are built on the same active fragment, GHRH(1-29). They act on the same pituitary receptor to stimulate pulsatile release of endogenous GH rather than supplying GH directly. What really separates them is not the receptor or the pathway but time: sermorelin is fleeting — its effect is measured in minutes — while CJC-1295, especially in its DAC form, binds circulating albumin and extends its action over days. This guide compares the two at an educational level: what they share, how they differ in duration, and why sermorelin had a clinical history that CJC-1295 never had. It is not medical advice and includes no dosing; today both are handled mainly as research-use-only (RUO) substances not approved for performance or anti-aging use.

	CJC-1295	Sermorelin
Class	Synthetic GHRH analog (GH secretagogue); acts on the pituitary GHRH receptor.	Synthetic GHRH analog (GH secretagogue); acts on the same pituitary GHRH receptor.
Structure	Modified GHRH(1-29) ('Modified GRF 1-29') engineered to resist enzymatic degradation; the DAC version adds a complex that covalently binds albumin.	29-amino-acid fragment of human GHRH (GHRH 1-29), essentially the native sequence, which retains full biological activity.
Half-life / duration	Prolonged: albumin binding (DAC) extends the half-life to several days; human studies estimate ~6-8 days of functional exposure.	Very short: native GHRH degrades within minutes, so its action is fleeting and brief.
Implied dosing frequency	Infrequent: the long DAC duration implies sustained exposure with widely spaced administrations.	Frequent: the brief action implies repeated administrations to maintain an effect on the axis.
Clinical track record	No approved clinical history; only short-duration human pharmacology studies in healthy volunteers.	Historical clinical use: FDA-approved as Geref (GH-deficiency diagnosis, 1990; pediatric deficiency, 1997), later discontinued.
Status (RUO / WADA)	Not approved by FDA/EMA/MHRA as a drug; sold as RUO. As a GH secretagogue it falls under WADA category S2 (prohibited at all times).	The approved product (Geref) is discontinued; today it circulates as compounded (US, by prescription) or RUO. Also a GH secretagogue under WADA category S2.

Same receptor, same family

The first thing to understand is that these two peptides are not rivals with different mechanisms but two variants of the same idea. Both are GHRH analogs — analogs of growth hormone-releasing hormone — and both are built on the same active fragment: GHRH(1-29), the first 29 amino acids that are enough to retain the biological activity of the native 44-amino-acid hormone. Sermorelin is essentially that native sequence; CJC-1295 is that same sequence modified to last longer. Both bind the GHRH receptor on the pituitary's somatotroph cells and stimulate pulsatile release of endogenous GH, which in turn raises IGF-1. This distinguishes them from direct GH administration: by acting upstream of the pituitary, they depend on a somatotroph population still able to respond and, at least in theory, preserve the body's own feedback controls (somatostatin, negative feedback from IGF-1) more than supplying GH directly would. In other words, they share the entry point into the system; what changes is how long they stay.

The key difference: duration of action

This is the real axis of the comparison. Native GHRH — and therefore sermorelin, which reproduces it almost literally — degrades within minutes: its action is fleeting, a brief stimulus that fades quickly and that, to sustain an effect on the axis, would imply repeated administrations. CJC-1295 was created precisely to solve that transience. In its base form ('Modified GRF 1-29') it already incorporates changes that make it more resistant to enzymatic degradation, and in its DAC (Drug Affinity Complex) version it goes further: the molecule covalently binds circulating albumin after injection, using it as a reservoir that releases it gradually. The result is a functional half-life that goes from minutes to several days — human pharmacology studies estimate on the order of 6-8 days of exposure. An interesting nuance in those studies is that, despite that prolonged exposure, the physiologic pulsatile pattern of GH secretion appears to persist rather than becoming continuous. The practical consequence of this difference is the implied dosing frequency: brief and repeated action versus sustained and spaced exposure. All of this is described at an educational level; the hub includes no dosing instructions.

Two very different trajectories: sermorelin's clinical history

Although they share a family, their real-world track records could not be more different. Sermorelin has a real, if dated, evidence base: it was studied through the 1980s and 90s, first as a diagnostic agent to assess pituitary GH reserve and later as a treatment. It was FDA-approved under the brand Geref — for diagnostic use in 1990 and for pediatric growth hormone deficiency in 1997 — and a controlled study in healthy older men (Corpas et al., 1992) described that twice-daily GRF(1-29) reversed the age-related decline in pulsatile GH secretion. That approved product, however, was discontinued for commercial reasons around 2008-2009. CJC-1295, by contrast, never had that trajectory: its human evidence is limited to a couple of short-duration pharmacology studies in healthy volunteers, with no long-term controlled trials on body composition, performance, or aging. This is an important asymmetry: one was an approved medicine that stopped being manufactured, the other never got past being a research compound.

Regulatory and quality status today

In the present, both converge on similar ground but by opposite routes. Neither is available as an approved medicine for general use: CJC-1295 never was, and sermorelin's Geref was discontinued. In the US, sermorelin keeps a particular legal path — it remains on the FDA's 503A bulks list, so licensed compounding pharmacies can prepare it with a valid prescription — while in the EU and UK it has no current marketing authorization. Outside those channels, both are sold and referenced as research chemicals (RUO), not medicines, without pharmaceutical manufacturing oversight or pharmacovigilance. As secretagogues of the GH/IGF-1 axis, both also fall under WADA's category S2 (peptide hormones and releasing factors), prohibited at all times for competitive athletes. And in both cases the dominant gray-market risk is the same: material of unverified purity, sterility, and labeling. The minimum verification is an independent third-party Certificate of Analysis covering identity, purity by HPLC, quantification, and mass spectrometry, with the lot number checked against the vial in hand.

Frequently asked questions

What is the main difference between CJC-1295 and sermorelin?: Duration of action. Both are GHRH analogs built on the same GHRH(1-29) fragment and act on the same pituitary receptor, but sermorelin reproduces the native hormone and degrades within minutes (fleeting action), while CJC-1295 — especially in its DAC form — binds albumin and extends its effect over days. They share a mechanism; they differ in how long they last. This answer is educational, not medical advice.
Why is sermorelin said to have had clinical use and CJC-1295 not?: Because sermorelin was FDA-approved as Geref, for GH-deficiency diagnosis (1990) and for pediatric growth hormone deficiency (1997), before being discontinued for commercial reasons around 2008-2009. CJC-1295 never had approval: its human evidence is limited to short-duration pharmacology studies in healthy volunteers. It is a difference in track record, not in current approval: today neither is an approved medicine for general use.
Are they approved today for performance or anti-aging use?: No. Neither is approved by the FDA, EMA, or MHRA for performance or anti-aging use; they are handled as research-use-only (RUO) substances, and sermorelin only retains a compounding pathway by prescription in the US. As GH secretagogues, both are additionally prohibited at all times for competitive athletes under WADA's S2 category. This information is educational.

✓ Last reviewed · 2026-07-24